← Leaderboards
Lixin Wan
Beth Israel Deaconess Medical Center
$2,483,048
Attributed
$2,483,048
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $376.8K · FY2014–25$500K$375K$250K$125K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,483,048 · 3
By mechanism
R01$1,491,935 · 1
R00$651,777 · 1
K99$339,336 · 1
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Michael B Atkins$4,622,469
- Harold Fisher Dvorak$13,877,917
- Laura E Benjamin$10,185,711
- Hiroyuki Inuzuka$1,016,239
Others in their field
Top investigators on “Ubiquitin-Protein Ligase”
- Rama K Mallampalli · Ohio State University$27,141,834
- Wenyi Wei · Brigham And Women'S Hospital$13,925,530
- Craig M Crews · Yale University$13,006,312
- Alexander J Varshavsky · California Institute Of Technology$12,266,340
- Michaela Ulrike Gack · Harvard Medical School$12,020,722
- Jeffrey Wade Harper · Dana-Farber Cancer Inst$11,601,860
Research focus
Ubiquitin-Protein LigaseXenograft ProcedureMouse ModelProteinsSignal TransductionUbiquitinationInsightMalignant NeoplasmsPlayPhysiologicalResistanceFutureTumorigenesisTumorExhibitsImmune SystemIn VitroIn VivoNovel StrategiesOncogenicCellsPathway InteractionsReportingBinding
Grant awards (10)
Characterizing oncogenic function of ITCH in melanoma$357,913
R01 · FY2025 · CA · contact PI
Characterizing oncogenic function of ITCH in melanoma$18,839
R01 · FY2024 · CA · contact PI
Characterizing oncogenic function of ITCH in melanoma$369,216
R01 · FY2023 · CA · contact PI
Characterizing oncogenic function of ITCH in melanoma$369,216
R01 · FY2022 · CA · contact PI
Characterizing oncogenic function of ITCH in melanoma$376,751
R01 · FY2021 · CA · contact PI
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment$148,607
R00 · FY2018 · CA · contact PI
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment$254,171
R00 · FY2017 · CA · contact PI
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment$248,999
R00 · FY2016 · CA · contact PI
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment$169,668
K99 · FY2015 · CA · contact PI
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment$169,668
K99 · FY2014 · CA · contact PI